Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI once-daily versus placebo for persistent asthma in Asian adolescents and adults
2015-004871-59Phase 3
- Sponsor
- GSK
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and vilanterol trifenatate in asthma (2 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in daily evening peak expiratory flow.
02
Drugs
fluticasonevilanterol trifenatate
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-004871-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004871-59.